Physician profile
David Marshall Smith
NPI 1306934997
$1,636.05
in general payments reported to CMS, 2019-2025
13 companies · $164 in 2025
The $164 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $228 · 2020: $24.98 · 2021: $125 · 2022: $392 · 2023: $555 · 2024: $148 · 2025: $164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $866.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $866.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $975.84 | 2019-2025 | Rinvoq, Linzess, Skyrizi |
| Celgene Corporation | $147.81 | 2022-2023 | Zeposia |
| Pfizer INC. | $140.40 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $108.76 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $69.09 | 2019 | |
| Phathom Pharmaceuticals, INC. | $37.45 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $32.66 | 2022 | |
| Genzyme Corporation | $29.53 | 2025 | |
| Shionogi INC | $26.51 | 2019 | |
| Madrigal Pharmaceuticals | $23.88 | 2024 | Resmetirom |
| Novo Nordisk INC | $19.30 | 2025 | Wegovy |
| Janssen Biotech, INC. | $13.34 | 2022 | |
| Glaxosmithkline, LLC. | $11.48 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.